<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Growing</title>
	<atom:link href="http://www.tapanray.in/tag/growing/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Horizon: Cloud, Rainbow And Smear</title>
		<link>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-horizon-cloud-rainbow-and-smear</link>
		<comments>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/#comments</comments>
		<pubDate>Mon, 09 Dec 2013 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cloudy]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monster]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sky]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[taint]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4400</guid>
		<description><![CDATA[Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend &#8230; <a href="http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Force Multiplier: An &#8220;Armageddon&#8221;: A Contender for Supremacy in the Generic Pharma World</title>
		<link>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world</link>
		<comments>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/#comments</comments>
		<pubDate>Mon, 22 Apr 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ANDAa]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Armageddon]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[contender]]></category>
		<category><![CDATA[defend]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[DMFs]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fastest]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guardian]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringing]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[multiplier]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[supremacy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Taro]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[triggering]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UK-MHRA]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2193</guid>
		<description><![CDATA[It is very important for any country to ensure access to most appropriate medicines for the patients as and when they require. In many disease areas such access can be remarkably improved through affordable generic drugs, which offer significant savings &#8230; <a href="http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India needs ‘Orphan Drugs Act (ODA)’ to counter growing threat of dreaded rare diseases and simultaneously boost global growth potential of the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 01 Nov 2010 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[dreaded]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[simultaneous]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=354</guid>
		<description><![CDATA[An orphan disease is a rare and uncommon disease and an ‘Orphan Drug’ is a pharmaceutical substance that has been developed to treat an orphan disease. The US FDA defines a rare disease, with a prevalence of 1 in 5,000 &#8230; <a href="http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilars –Indian Pharmaceutical Companies are sharpening their focus on fast growing Oncology segment</title>
		<link>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment</link>
		<comments>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/#comments</comments>
		<pubDate>Mon, 13 Jul 2009 01:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[sharpening]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=836</guid>
		<description><![CDATA[The global market for Bio-pharmaceuticals is estimated to be around US$ 50 billion by the next year. Currently about 25% of New Molecular Entities (NMEs) under development are of biotech origin. Indian pharmaceutical majors like Dr. Reddy’s Laboratories (DRL), Reliance &#8230; <a href="http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-indian-pharmaceutical-companies-are-sharpening-their-focus-on-fast-growing-oncology-segment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Growing menace of counterfeit drugs in India: why is the domestic pharmaceutical industry still so apprehensive with the new Amendments of the ACT?</title>
		<link>http://www.tapanray.in/growing-menace-of-counterfeit-drugs-in-india-why-is-the-domestic-pharmaceutical-industry-still-so-apprehensive-with-the-new-amendments-of-the-act-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-menace-of-counterfeit-drugs-in-india-why-is-the-domestic-pharmaceutical-industry-still-so-apprehensive-with-the-new-amendments-of-the-act-2</link>
		<comments>http://www.tapanray.in/growing-menace-of-counterfeit-drugs-in-india-why-is-the-domestic-pharmaceutical-industry-still-so-apprehensive-with-the-new-amendments-of-the-act-2/#comments</comments>
		<pubDate>Wed, 29 Apr 2009 00:30:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Amendments]]></category>
		<category><![CDATA[apprehensive]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[so]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[why]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=903</guid>
		<description><![CDATA[The growing menace of Counterfeit drugs has remained a serious threat to the healthcare space of India. Do we have any credible data to assess the magnitude of this menace in India? No we do not have, as yet. At &#8230; <a href="http://www.tapanray.in/growing-menace-of-counterfeit-drugs-in-india-why-is-the-domestic-pharmaceutical-industry-still-so-apprehensive-with-the-new-amendments-of-the-act-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-menace-of-counterfeit-drugs-in-india-why-is-the-domestic-pharmaceutical-industry-still-so-apprehensive-with-the-new-amendments-of-the-act-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fixed Dose Combination’ drugs market in India is growing faster &#8211; are there enough regulatory checks and balances to prevent market entry of ‘irrational combinations’ to ensure patients’ safety?</title>
		<link>http://www.tapanray.in/fixed-dose-combination-drugs-market-in-india-is-growing-faster-are-there-enough-regulatory-checks-and-balances-to-prevent-market-entry-of-irrational-combinations-to-ensure/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fixed-dose-combination-drugs-market-in-india-is-growing-faster-are-there-enough-regulatory-checks-and-balances-to-prevent-market-entry-of-irrational-combinations-to-ensure</link>
		<comments>http://www.tapanray.in/fixed-dose-combination-drugs-market-in-india-is-growing-faster-are-there-enough-regulatory-checks-and-balances-to-prevent-market-entry-of-irrational-combinations-to-ensure/#comments</comments>
		<pubDate>Sun, 26 Apr 2009 18:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[balances]]></category>
		<category><![CDATA[checks]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[ensure]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=909</guid>
		<description><![CDATA[The WHO Model of FDCs:The 2005 ʹProcedure to update and disseminate the WHO Model List of Essential Medicines, Criteria for Selection&#8216; includes the following statement regarding fixed dose combination products (FDCs):ʺMost essential medicines should be formulated as single compounds. Fixed‐dose &#8230; <a href="http://www.tapanray.in/fixed-dose-combination-drugs-market-in-india-is-growing-faster-are-there-enough-regulatory-checks-and-balances-to-prevent-market-entry-of-irrational-combinations-to-ensure/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fixed-dose-combination-drugs-market-in-india-is-growing-faster-are-there-enough-regulatory-checks-and-balances-to-prevent-market-entry-of-irrational-combinations-to-ensure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare services in India &#8230; growing disparity between urban and rural population – can ‘Telemedicine’ play a significant role?</title>
		<link>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role</link>
		<comments>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/#comments</comments>
		<pubDate>Sun, 05 Apr 2009 06:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[disparity]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[e-healthcare]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[play]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=923</guid>
		<description><![CDATA[Healthcare Industry in India is currently valued at US$ 35 billion. This industry is expected to record a turnover of US$ 75 billion in 2012 and US$ 150 billion in 2017, reports Technopak Advisors in their report titled “India Healthcare &#8230; <a href="http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-services-in-india-growing-disparity-between-urban-and-rural-population-can-telemedicine-play-a-significant-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
